NanoString Technologies (NSTG) Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NanoString Technologies in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NSTG shares.
View NSTG analyst ratings or view top-rated stocks.

5 brokerages have issued 1-year price objectives for NanoString Technologies' stock. Their NSTG share price forecasts range from $14.00 to $24.00. On average, they expect the company's stock price to reach $17.83 in the next year. This suggests a possible upside of 211.2% from the stock's current price.
View analysts price targets for NSTG or view top-rated stocks among Wall Street analysts.

NanoString Technologies' stock was trading at $7.97 at the beginning of 2023. Since then, NSTG stock has decreased by 28.1% and is now trading at $5.73.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our NSTG earnings forecast.

NanoString Technologies, Inc. (NASDAQ:NSTG) announced its quarterly earnings data on Wednesday, May, 3rd. The biotechnology company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by $0.16. The biotechnology company earned $35.81 million during the quarter, compared to analysts' expectations of $33.13 million. NanoString Technologies had a negative net margin of 122.19% and a negative trailing twelve-month return on equity of 252.96%. The business's quarterly revenue was up 15.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.86) EPS.

ETFs with the largest weight of NanoString Technologies (NASDAQ:NSTG) stock in their portfolio include ROBO Global Healthcare Technology and Innovation ETF (HTEC), Global X Genomics & Biotechnology ETF (GNOM), Invesco Nasdaq Future Gen 200 ETF (QQQS), WisdomTree BioRevolution Fund (WDNA), Principal Healthcare Innovators ETF (BTEC), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares U.S. Medical Devices ETF (IHI).

NanoString Technologies updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $175.00 million-$185.00 million, compared to the consensus revenue estimate of $174.78 million.

36 employees have rated NanoString Technologies Chief Executive Officer Brad Gray on Glassdoor.com. Brad Gray has an approval rating of 65% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoString Technologies investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Aegean Marine Petroleum Network (ANW), Chipotle Mexican Grill (CMG), Precision Drilling (PD), AutoZone (AZO), Designer Brands (DBI), Bank of the Ozarks (OZRK) and Vista Outdoor (VSTO).

NanoString Technologies trades on the NASDAQ under the ticker symbol "NSTG."

NanoString Technologies' stock is owned by a variety of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (10.39%), BlackRock Inc. (10.06%), Platinum Investment Management Ltd. (2.60%), State Street Corp (2.38%), Bank of America Corp DE (2.27%) and Assenagon Asset Management S.A. (1.90%). Insiders that own company stock include Charles P Waite Jr, Elisha W Finney, Gregory Norden, J Chad Brown, Joseph M Beechem, K Thomas Bailey, Kirk Malloy, R Bradley Gray, Robert Hershberg and William Young.
View institutional ownership trends.

Shares of NSTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NSTG stock can currently be purchased for approximately $5.73.

NanoString Technologies (NASDAQ:NSTG) has a market capitalization of $271.20 million and generates $127.26 million in revenue each year. The biotechnology company earns $-159,540,000.00 in net income (profit) each year or ($3.47) on an earnings per share basis.

The company employs 766 workers across the globe.

NanoString Technologies' mailing address is 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109. The official website for the company is www.nanostring.com. The biotechnology company can be reached via phone at (888) 358-6266, via email at dfarrell@nanostring.com, or via fax at 206-378-6288.